Supreme Court Confronts Glyphosate Labeling Standards Under FIFRA

The U.S. Supreme Court convened on April 27, 2026, to resolve a legal dispute regarding the labeling of glyphosate-based herbicides, specifically Roundup, and its association with cancer risk. The case, Monsanto Co. v. Durnell, focuses on the interpretation of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which regulates pesticide labeling. The Court’s decision could influence how chemical risks are communicated to consumers and affect corporate liability standards, with broader implications for regulatory policy and public health. The ruling, expected by April 29, 2026, will determine whether states can enforce additional labeling requirements or if federal preemption under FIFRA will override state mandates.

“changes to safety warnings must occur through FIFRA’s formal cancellation process rather than state litigation.”

Background: Roundup and Legal Challenges

Roundup, developed by Swiss agrochemical company Syngenta and marketed by Monsanto (now part of Bayer AG), has been widely used in agriculture since the 1970s. In 2023, a Missouri jury awarded $1.25 million to a plaintiff who alleged Roundup caused non-Hodgkin lymphoma, marking a significant legal development. This verdict formed the basis of the current case, which challenges Monsanto’s labeling practices. Bayer, which acquired Monsanto in 2018, has faced numerous lawsuits over Roundup. The company reached a $7.25 billion settlement in 2023 to resolve thousands of cancer-related claims. Despite these financial commitments, the Trump administration, through Principal Deputy Solicitor General Sarah Harris, has supported Monsanto’s position, arguing that states cannot impose labeling requirements conflicting with EPA-approved standards. Protests outside the Supreme Court during the case reflected public opposition to Monsanto’s stance, with demonstrators demanding stricter labeling and corporate accountability.

Legal Framework: FIFRA and EPA’s Role

FIFRA requires pesticide labels to include “all information reasonably necessary for the proper and safe use” of the product. Monsanto asserts that state-mandated cancer warnings conflict with EPA-approved labels and violate FIFRA’s uniformity requirements by adding requirements beyond federal law. The company’s attorney, Paul Clement, argued that changes to safety warnings must occur through FIFRA’s formal cancellation process rather than state litigation. The EPA’s 2023 risk assessment, which downgraded glyphosate’s cancer risk classification, became a central point of contention. The agency’s methodology relied on industry-funded studies, drawing criticism from environmental advocates. During oral arguments, justices questioned Monsanto on whether states could act more swiftly on new safety information without conflicting with EPA findings. Chief Justice John Roberts noted states might respond to new data faster than the federal government, while Justice Brett Kavanaugh raised concerns about retroactive penalties if EPA later deemed compliant labels misbranded.

Key Uncertainties: Preemption and Regulatory Authority

The case centers on whether state tort claims imposing additional labeling requirements are preempted by federal law under FIFRA. Monsanto contends that the EPA’s 2023 assessment, which concluded glyphosate is safe, preempts state actions. Critics, however, argue the EPA’s evaluation excluded peer-reviewed studies linking glyphosate to cancer, raising concerns about regulatory bias. The Court’s interpretation of FIFRA’s preemption clause will determine whether states retain authority to mandate safety warnings absent conclusive federal findings. Oral arguments suggested a majority leaning toward dismissing the lawsuit, aligning with FIFRA’s preemption clause as interpreted in prior cases like Bates v. Dow AgroSciences.

“states might respond to new data faster than the federal government”

Implications for Corporate Liability and Regulatory Policy

The ruling’s financial impact is significant for Bayer, which has already spent over $7.25 billion resolving Roundup-related claims. A decision favoring Monsanto could reduce future litigation costs but may also encourage corporations to downplay risks, potentially harming consumers. Conversely, a ruling upholding state labeling rights could establish a precedent for stricter pesticide oversight. The case highlights a broader tension between scientific evidence and regulatory policy. While the EPA’s 2023 assessment downgraded glyphosate’s cancer risk, critics argue the methodology lacks transparency and rigor. The Court’s decision will shape how chemical risks are communicated and whether states retain the authority to mandate safety warnings absent conclusive federal findings.

Conclusion: A Defining Moment for Regulatory Policy

The Supreme Court’s consideration of Roundup labeling underscores a fundamental tension in modern regulatory policy: balancing scientific evidence with economic interests. While the Court’s final ruling remains pending, the case has already ignited a national debate about consumer rights, corporate accountability, and the role of science in policymaking. The decision will determine whether states can impose additional safety requirements on pesticides or if federal preemption will prevail, with far-reaching consequences for public health and corporate responsibility.